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distribution of the study patients was as follows: 20% in the 3-5 year group, 26% in the 6-12 year group, 13% in the 13-19 year group, and 39% in the age range of over 20 years.
Study design
This was a before and after study, carried out in a large HMO. The patients were followed for at least one year by a primary care physician before the allergy evaluation (AE) and for at least one year after the AE. Loss to follow-up appears not to have been relevant in this context since one of the study criteria for patient selection was that all patients had to have a full one year follow-up before and after AE.
Analysis of effectiveness
The principle employed in the analysis of effectiveness appears to have been treatment completers only (by implication from the patient selection criteria). The clinical outcome was the overall morbidity of asthma as measured by the number of sick office visits, acute care visits, hospitalisation, and average hospital days.
Effectiveness results
The effectiveness results were as follows:
(1) overall number of sick office visits, 45% decrease after the AE (308 to 169, p=0.0001) -distribution as follows: 29% in the 3-5 year age group, 48% in the 6-12 year age group, 64% in teenagers, and 46% in adults;
(2) the number of acute care visits after the AE, 55% decrease, (266 to 118, p=0.0001) -distribution as follows: 39% in the 3-5 year age group, 77% in the 6-12 year age group, 79% in teenagers, and 44% in adults; (3) the number of hospitalisations after the AE, 67% decrease (34 to 11, p=0.001) -distribution as follows: 37% in the 3-5 year age group, 77% in the 6-12 year age group, 100% in teenagers, and 72% in adults); (4) average hospital days, a decrease from 4 to 2.5 days, (p<0.09).
Clinical conclusions
After an allergy consultation, there was an overall decreased morbidity of asthma with fewer hospitalisations, shorter hospitalisations, less acute care (ER visits), and less sick office visits. However, in the 3-5 year-old age group there was somewhat less improvement than in the older age group. This may reflect the prominent triggering role of viral infections in this age group.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported.
Direct costs
Costs were not discounted as they were incurred in a one year time period for each health technology. Quantities were reported separately from the costs. Cost items were reported separately. The cost analysis covered the costs of sick office visits, acute care (ER), and hospitalisations. The perspective adopted in the cost analysis was not explicitly specified. Retrospective chart review was the source of resource use data. Fee for service charges were used to estimate costs. The standard per diem charge was used for hospital costs. The date of the price data was not explicitly specified.
In view of the retrospective nature of the study design, and the lack of sensitivity analysis and statistical analysis of the costs, the study results should be interpreted with some degree of caution. The issue of generalisability to other settings or countries was not addressed although appropriate comparisons were made with other studies; it was reported that the study results may not be comparable with another study (National Jewish Center model) with a study sample consisting of chronic, severe, life-threatening asthma. The study results do not appear to have been reported selectively. The study enrolled patients with moderate to severe asthma and this was reflected in the authors' conclusion.
Implications of the study
In spite of the study limitations, the outcome is strongly indicative of the benefits of an allergy/asthma consultation. In the study managed care setting, the authors recommended that all moderate to severe asthmatic patients should have an allergy/asthma consultation.
Source of funding
None stated.
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